DID YOU KNOW? Medtronic CGM has an +80% approval rate through insurance.**

MiniMed™ 670G

By submitting this form you are consenting to and confirm the following:

  • That Medtronic can communicate with you regarding our diabetes products by telephone, fax, mail and/or e-mail.
  • That Medtronic stores information, including personal health information, on systems located outside of Canada.
  • That you have read and are aware of our privacy policy.
  • That you grant Medtronic of Canada permission to send you updates on diabetes and diabetes technology.
  • You may revoke this permission at any time by emailing medtronicdiabetescc@medtronic.com
  • Medtronic respects the confidentiality of personal information. We assure you we will not share your personal information, except as otherwise noted in our privacy policy.


If you've been considering a change, this could be a great time to make the move to our latest technology. Fill out the form to learn more.

MiniMed™ 670G

Individual results may vary. The MiniMed 670G is indicated for people living with type 1 diabetes, seven years of age and older.

*90% reduction in injections assumes four injections per day for 30 days and one infusion set change every two to three days. **Data on file. 2019.

1. Mueckler, JR et al. Real-World Assessment of Former MDI Patients’ Experience on the Medtronic MiniMed™ 670G Hybrid Closed-Loop System (n=47). Poster presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD); 2017 February 14-17, Vienna, Austria